# 18F-PSMA PET and MRI in the Primary Staging of Prostate Cancer Patients

> **NCT05141760** · PHASE2 · COMPLETED · sponsor: **University of Alberta** · enrollment: 150 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DIAGNOSTIC_TEST:** PSMA-1007 Positron Emission Tomography (PET) scan and 3T Magnetic Resonance Imaging (MRI)

## Key facts

- **NCT ID:** NCT05141760
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-10
- **Primary completion:** 2023-06-15
- **Final completion:** 2023-06-15
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2024-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05141760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05141760, "18F-PSMA PET and MRI in the Primary Staging of Prostate Cancer Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05141760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*